Advances in Tumor Immunology and Immunotherapy

Joseph D Rosenblatt, Eckhard R. Podack, Glen N Barber, Augusto Ochoa

Research output: Book/ReportBook

Abstract

Recent advances in understanding of fundamental immunology have created new insights into the dynamic interactions between tumors and the immune system. This includes new understanding of T- and B-cell interaction, immune inhibitory mechanisms including the biology of T regulatory cells, myeloid suppressor cells, and dendritic cell subsets. Enhanced understanding of mechanisms underlying T-cell anergy such as arginine deprivation, immunosuppressive cytokines, defective innate and interferon response pathways, and NKG2D downregulation have all provided new insight into suppression of anti-tumor immunity and tumor evasion. In addition to emerging understanding of tumor evasion, new immune targets such as CTLA4 blockade, NK stimulatory receptors, manipulation of the antigen processing and presentation, cytokine and costimulatory responses all provide new possibilities for enhancing anti-tumor immunity even in tumors previously felt to be resistant to immune attack. Several of these strategies have already been realized in the clinic. The volume will explore evolving paradigms in antigen presentation, dendritic cell biology, the innate response and immunosuppressive mechanisms, and emerging strategies for manipulation of the immune system for therapeutic benefit that have realized success in neuroblastoma, leukemia, melanoma, lung cancer, and allogeneic transplantation. Early successes as well as failures will be highlighted to provide a snapshot of the state of clinical immunotherapy with an eye to future possibilities such as combination therapies, adoptive T-cell transfer, and the retargeting of immune cells via T-cell receptor engineering.

Original languageEnglish (US)
PublisherSpringer New York
Number of pages371
ISBN (Electronic)9781461488095
ISBN (Print)9781461488088
DOIs
StatePublished - Jan 1 2014

Fingerprint

Allergy and Immunology
Immunotherapy
Antigen Presentation
Neoplasms
Immunosuppressive Agents
Dendritic Cells
Immune System
Immunity
Cytokines
Tumor Escape
Cell Engineering
T-Lymphocytes
Lung Transplantation
Adoptive Transfer
Homologous Transplantation
Regulatory T-Lymphocytes
Myeloid Cells
T-Cell Antigen Receptor
Neuroblastoma
Cell Communication

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Advances in Tumor Immunology and Immunotherapy. / Rosenblatt, Joseph D; Podack, Eckhard R.; Barber, Glen N; Ochoa, Augusto.

Springer New York, 2014. 371 p.

Research output: Book/ReportBook

Rosenblatt, Joseph D ; Podack, Eckhard R. ; Barber, Glen N ; Ochoa, Augusto. / Advances in Tumor Immunology and Immunotherapy. Springer New York, 2014. 371 p.
@book{284abaf284564bdfbdd526fc7a6b854f,
title = "Advances in Tumor Immunology and Immunotherapy",
abstract = "Recent advances in understanding of fundamental immunology have created new insights into the dynamic interactions between tumors and the immune system. This includes new understanding of T- and B-cell interaction, immune inhibitory mechanisms including the biology of T regulatory cells, myeloid suppressor cells, and dendritic cell subsets. Enhanced understanding of mechanisms underlying T-cell anergy such as arginine deprivation, immunosuppressive cytokines, defective innate and interferon response pathways, and NKG2D downregulation have all provided new insight into suppression of anti-tumor immunity and tumor evasion. In addition to emerging understanding of tumor evasion, new immune targets such as CTLA4 blockade, NK stimulatory receptors, manipulation of the antigen processing and presentation, cytokine and costimulatory responses all provide new possibilities for enhancing anti-tumor immunity even in tumors previously felt to be resistant to immune attack. Several of these strategies have already been realized in the clinic. The volume will explore evolving paradigms in antigen presentation, dendritic cell biology, the innate response and immunosuppressive mechanisms, and emerging strategies for manipulation of the immune system for therapeutic benefit that have realized success in neuroblastoma, leukemia, melanoma, lung cancer, and allogeneic transplantation. Early successes as well as failures will be highlighted to provide a snapshot of the state of clinical immunotherapy with an eye to future possibilities such as combination therapies, adoptive T-cell transfer, and the retargeting of immune cells via T-cell receptor engineering.",
author = "Rosenblatt, {Joseph D} and Podack, {Eckhard R.} and Barber, {Glen N} and Augusto Ochoa",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/978-1-4614-8809-5",
language = "English (US)",
isbn = "9781461488088",
publisher = "Springer New York",

}

TY - BOOK

T1 - Advances in Tumor Immunology and Immunotherapy

AU - Rosenblatt, Joseph D

AU - Podack, Eckhard R.

AU - Barber, Glen N

AU - Ochoa, Augusto

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Recent advances in understanding of fundamental immunology have created new insights into the dynamic interactions between tumors and the immune system. This includes new understanding of T- and B-cell interaction, immune inhibitory mechanisms including the biology of T regulatory cells, myeloid suppressor cells, and dendritic cell subsets. Enhanced understanding of mechanisms underlying T-cell anergy such as arginine deprivation, immunosuppressive cytokines, defective innate and interferon response pathways, and NKG2D downregulation have all provided new insight into suppression of anti-tumor immunity and tumor evasion. In addition to emerging understanding of tumor evasion, new immune targets such as CTLA4 blockade, NK stimulatory receptors, manipulation of the antigen processing and presentation, cytokine and costimulatory responses all provide new possibilities for enhancing anti-tumor immunity even in tumors previously felt to be resistant to immune attack. Several of these strategies have already been realized in the clinic. The volume will explore evolving paradigms in antigen presentation, dendritic cell biology, the innate response and immunosuppressive mechanisms, and emerging strategies for manipulation of the immune system for therapeutic benefit that have realized success in neuroblastoma, leukemia, melanoma, lung cancer, and allogeneic transplantation. Early successes as well as failures will be highlighted to provide a snapshot of the state of clinical immunotherapy with an eye to future possibilities such as combination therapies, adoptive T-cell transfer, and the retargeting of immune cells via T-cell receptor engineering.

AB - Recent advances in understanding of fundamental immunology have created new insights into the dynamic interactions between tumors and the immune system. This includes new understanding of T- and B-cell interaction, immune inhibitory mechanisms including the biology of T regulatory cells, myeloid suppressor cells, and dendritic cell subsets. Enhanced understanding of mechanisms underlying T-cell anergy such as arginine deprivation, immunosuppressive cytokines, defective innate and interferon response pathways, and NKG2D downregulation have all provided new insight into suppression of anti-tumor immunity and tumor evasion. In addition to emerging understanding of tumor evasion, new immune targets such as CTLA4 blockade, NK stimulatory receptors, manipulation of the antigen processing and presentation, cytokine and costimulatory responses all provide new possibilities for enhancing anti-tumor immunity even in tumors previously felt to be resistant to immune attack. Several of these strategies have already been realized in the clinic. The volume will explore evolving paradigms in antigen presentation, dendritic cell biology, the innate response and immunosuppressive mechanisms, and emerging strategies for manipulation of the immune system for therapeutic benefit that have realized success in neuroblastoma, leukemia, melanoma, lung cancer, and allogeneic transplantation. Early successes as well as failures will be highlighted to provide a snapshot of the state of clinical immunotherapy with an eye to future possibilities such as combination therapies, adoptive T-cell transfer, and the retargeting of immune cells via T-cell receptor engineering.

UR - http://www.scopus.com/inward/record.url?scp=85028502437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028502437&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-8809-5

DO - 10.1007/978-1-4614-8809-5

M3 - Book

AN - SCOPUS:85028502437

SN - 9781461488088

BT - Advances in Tumor Immunology and Immunotherapy

PB - Springer New York

ER -